Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Results From at Least 1-Year Follow-Up in all Patients

被引：0

作者：

Frigault, Matthew ^{[1
]}

Rosenblatt, Jacalyn ^{[2
]}

Dhakal, Binod ^{[3
]}

Raje, Noopur ^{[4
]}

Cook, Daniella ^{[1
]}

Gaballa, Mahmoud ^{[5
]}

Emmanuel-Alejandro, Estelle ^{[2
]}

Nissen, Danielle ^{[3
]}

Banerjee, Kamalika ^{[6
]}

Rotte, Anand ^{[6
]}

Heery, Christopher ^{[6
]}

Avigan, David ^{[2
]}

Jakubowiak, Andrzej ^{[7
]}

Bishop, Michael ^{[7
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[3] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[4] Massachusetts Gen Hosp, Boston, MA 02114 USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Arcellx Inc, Redwood City, CA USA

[7] Univ Chicago, Chicago, IL 60637 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

MM; multiple myeloma; BCMA; plasma cell; anitocabtagene autoleucel;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-364

引用

页码：S553 / S553

页数：1

共 50 条

[31] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
Hans C. Lee
Jatin J. Shah
Lei Feng
Elisabet E. Manasanch
Rebecca Lu
Ashley Morphey
Brandon Crumpton
Krina K. Patel
Michael L. Wang
Raymond Alexanian
Sheeba K. Thomas
Donna M. Weber
Robert Z. Orlowski
Blood Cancer Journal, 9
[32] Pomalidomide and Dexamethasone Treatment for ≥ 1 Year in Renally Impaired Patients With Relapsed or Refractory Multiple Myeloma
Weisel, Katja
Dimopoulos, Meletios A.
Cook, Mark
Ramasamy, Karthik
De La Rubia, Javier
Ardizzoia, Antonio
Krauth, Maria Theresa
Jaccard, Arnaud
Van de Donk, Niels
Kueenburg, Elisabeth
Di Micco, Antonia
Rosettani, Barbara
Atiba-Davies, Margaret
Bacon, Pamela
Sonneveld, Pieter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E284 - E285
[33] Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study
Cohen, Adam D.
Hari, Parameswaran
Htut, Myo
Berdeja, Jesus G.
Usmani, Saad Z.
Madduri, Deepu
Olyslager, Yunsi
Goldberg, Jenna D.
Schecter, Jordan M.
Jackson, Carolyn C.
Gries, Katharine S.
Fastenau, John M.
Valluri, Satish
Deraedt, William
Akram, Muhammad
Crawford, Rebecca
Morrison, Ross
Doward, Lynda
Morgan, Kate
ten Seldam, Silene
Jakubowiak, Andrzej
Jagannath, Sundar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (01): : 68 - 77
[34] Remission in schizophrenia: Results from a 1-year follow-up observational study
Ciudad, Antonio
Alvarez, Enric
Bobes, Julio
San, Luis
Polavieja, Pepa
Gilaberte, Inmaculada
SCHIZOPHRENIA RESEARCH, 2009, 108 (1-3) : 214 - 222
[35] Elotuzumab In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study.
Jakubowiak, Andrzej J.
Benson, Don M., Jr.
Bensinger, William
Siegel, David S.
Zimmerman, Todd M.
Mohrbacher, Ann
Richardson, Paul G.
Afar, Daniel E. H.
Singhal, Anil K.
Anderson, Kenneth C.
BLOOD, 2010, 116 (21) : 1245 - 1245
[36] Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study
Rodriguez-Otero, Paula
Dholaria, Bhagirathbhai
Askari, Elham
Reece, Donna E.
van de Donk, Niels W. C. J.
Chari, Ajai
Goldschmidt, Hartmut
Krishnan, Amrita Y.
Martin, Thomas
Mateos, Maria-Victoria
Giles, Daniel Morillo
Rodriguez, Cesar
Rosinol, Laura
San-Miguel, Jesus F.
Sureda, Anna
Waesch, Ralph
Weisel, Katja
Verona, Raluca I.
Lin, Shun Xin Wang
Prior, Thomas J.
Weiss, Brendan M.
Wade, Mark
Goldberg, Jenna D.
Oriol, Albert
Hari, Parameswaran
BLOOD, 2021, 138
[37] 2-Year Follow-Up Results From the Phase 1-2 Study of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 10 - 11
[38] Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation
Schneidawind, Corina
Duerr-Stoerzer, Silke
Faul, Christoph
Kanz, Lothar
Weisel, Katja
Bethge, Wolfgang
Schneidawind, Dominik
CLINICAL TRANSPLANTATION, 2017, 31 (07)
[39] Collaboration with drug treatment by schizophrenic patients with and without psychoeducational training: results of a 1-year follow-up
Hornung, WP
Klingberg, S
Feldmann, R
Schonauer, K
Monking, HS
ACTA PSYCHIATRICA SCANDINAVICA, 1998, 97 (03) : 213 - 219
[40] PSYCHOEDUCATIONAL-PSYCHOTHERAPEUTIC TREATMENT OF SCHIZOPHRENIC-PATIENTS AND THEIR RELATIVES - RESULTS OF A 1-YEAR FOLLOW-UP
HORNUNG, WP
HOLLE, R
MONKING, HS
KLINGBERG, S
BUCHKREMER, G
NERVENARZT, 1995, 66 (11): : 828 - 834

← 1 2 3 4 5 →